EBF 2021 Cyberconnect Events:

Focus Workshop: Peptides & Proteins with (LC-)MS

17-18 June 2021

Day 1 (all times in CET, Brussels Time Zone)

12:30	**12:45**	**Coming online**
12:45	**13:00**	**Getting started - Welcome** Philip Timmerman - EBF
13:00	**13:20**	**Introduction to the workshop** Matthew Barfield - on behalf of the EBF *Why this workshop?*
13:20	**14:40**	**Session 1 - Scientific Challenges (e.g. reagents, free total, intact vs digested)**
13:20	13:40	Carsten Krantz - Novartis *Hybrid LBA-LCMS for ADA detection*
13:40	14:00	Daniel Vidler - Arcinova – A Quotient Sciences Business *Identifying Peptide Markers From Mycobacterial Protein Digests – Development of a High-Resolution LC-MS Assay*
14:00	14:20	Matthias Sury - Celerion *Key Reagent Release Testing by LC-HRMS*
14:20	14:40	Chris Williams - QPS *Development of a hybrid method for quantification of a therapeutic protein differing by a single amino acid from the endogenous form*
14:40	**15:10**	Break
15:10	**18:30**	**Session 2: Scientific developments (new tools)**
15:10	15:30	Julien Peltier - GlaxoSmithKline *Characterisation and Quantification of Therapeutic Antibodies by Incorporating Response Bias Correction using Affinity Capture and Intact Protein LC-MS.*
15:30	15:50	Ke Li - Frontage Labs *Development and validation of a LC/MS method for the quantification of fascin in human serum*
15:50	16:10	Thomas Schneider - BiognoSYS AG *Context of Use Validation of a Data Independent Acquisition based Deep Proteome Quantification Approach*
16:10	16:30	Lei Xiong - Sciex *Improved LC-MRM workflow for cyclic peptide quantification on natriuretic peptide family*
16:30	16:40	Short Q&A
		Short logistic break
17:00	17:20	James Marr - MSD *Improvements in Immunoprecipitation and Digestion Efficiencies for Monoclonal Antibodies in Pharmacokinetic Studies using LC-MS/MS for Analysis*
17:20	17:40	Szabolcs Szarka - LGC *Utilizing high-resolution mass spectrometry to improve the sensitivity of a therapeutic protein assay*
17:40	18:00	Anton Rosenbaum - AstraZeneca *Comparison of Bioanalytical Methods for Pharmacokinetic Assessments of ADC*
18:00	18:30	Session 2 Q&A
18:30		**End of Day 1**

Day 2 (all times in CET, Brussels Time Zone)

12:45	**13:00**	**Coming online**
13:00	**14:30**	**Session 3: how to interpret the data (e.g. biological specificity *vs.* analytical specificity, which data are 'true'?**
13:00	13:10	Philip Timmerman - EBF *Introduction to the session: Turning Scientific challenges challenges into opportunities*
13:10	13:30	Oriol Peris Serrano - Charles River Laboratories *The Impact of Assay Acceptance Criteria on Derived Data – Pharmacokinetic Assessment Through Simulation*
13:30	13:50	Gregor Jordan - F. Hoffmann-La Roche *Is correct quantification of free/active drug concentrations by hybrid LC-MS possible? An evaluation applying the "free analyte QC concept"*
13:50	14:10	Nico van de Merbel - PRA-HS/U. Groningen *Analytical consequences of the in vivo deamidation of trastuzumab and pertuzumab: comparison of the results of three bioanalytical platforms*
14:10	14:30	*Session 3 Q&A and panel discussion*
14:30	**14:50**	*Break*
14:50	**16:20**	**Session 4 - Defining a bioanalytical strategy for peptide/protein: which assay when and why?**
14:50	15:00	Iain Love - on behalf of the EBF *Introduction to the session: Questions to consider when buidling a bioanalytical strategy for proteins*
15:00	15:20	Rita Martello - Merck KGaA *How to develop a bionalaytical strategy for therapeutic proteins*
15:20	15:40	Shashank Gorityala - Covance *LCMS-based strategies for the quantitation of protein biotherapeutics*
15:40	16:00	Emmanuel Njumbe Ediage, Janssen R&D *Challenges in developing an LC-MS/MS assay for the quantification of Pegasys; what are we measuring?*
16:00	16:20	Session 4 Q&A and panel discussion
16:20	**16:40**	*Break*
16:40	**18:20**	**Session 5 - Regulatory challenges – experience and industry recommendations**
16:40	17:00	Amanda Wilson - on behalf of the EBF *Introduction to the session: EBF FB from the survey*
17:00	17:20	Case studies & scientific and regulatory challenges on combining MS and LBA Tsvetelina Ivanova, Comac-Medical *Pharmacokinetic analysis using LBA and MS concentration data – was this a real challenge?*
17:20	17:40	William Mylott, PPD *Bioanalytical Method Validations: Taking a 'Hybrid Approach'*
17:40	18:00	Eric Thomas, Covance by Labcorp *Perspectives on Performance and Requirements for Protein MS Assays*
18:00	18:20	**Closing Panel discussion**: where regulatory and scientific challegens for protein analysis meet.
18:20		Closing comments and Adjourn

EBF

Organising Committee:

Matthew Barfield (F. Hoffmann-La Roche), Iain Love (Charles River Laboratories), Amanda Wilson (AstraZeneca), Nico van de Merbel (PRA-HS) and Philip Timmerman (EBF)